All News

Officials with the FDA have granted breakthrough therapy designation to trastuzumab deruxtecan (Enhertu, AstraZeneca and Daiichi Sankyo) for the treatment of HER2-mutant metastatic non-small cell lung cancer (NSCLC).

Community pharmacies are ideally positioned to support reopening efforts and recovery plans amid the coronavirus disease 2019 pandemic. 

Rucaparib is the first PARP inhibitor that has been approved in a prostate cancer setting.

Moderna’s coronavirus disease 2019 vaccine candidate, mRNA-1273, showed promise in interim data from its phase 1 study.

"I have to admit that in all 39 years of my career as a community pharmacist, I have never seen a drug that was the center of such intense political discussion."

In part 2 of our interview, Devin English, assistant professor at Rutgers School of Health, joined Drug Topics® to discuss how COVID-19 is disproportionately affecting minorities.

A new study found that the use of PCSK9 inhibitors with maximally tolerated statins does not negatively affect the mental cognition of patients.

New digital health products are providing more insight into data and the opportunity for real-time patient interaction.

Heart disease is so common among Americans that it claims 1 life every 37 seconds.

A presentation from the 2020 PQA Annual Meeting examined how employers can engage in improving quality of care for those dependent on opioids.

Pharmacists are often the most accessible health care professionals, which is why a lack of access to pharmacies can have a detrimental effect on patients, especially those with chronic conditions. 

Thank you to pharmacy staff on the front lines. 

Investigators are looking for a new way to improve upon a 100-year-old vaccine.

On Tuesday, California Governor Gavin Newsom granted California pharmacists the ability to order and administer coronavirus disease 2019 (COVID-19) tests.

A presentation from the 2020 PQA Annual Meeting discussed the emerging focus on social determinants of health within the industry and how pharmacists can address the issue.

Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.

Purdue University College of Pharmacy in West Lafayette, Indiana, helped its students graduate in record time this spring.

Investigators are developing a new needle-less vaccine delivery method that would eliminate the need for refrigeration and could significantly reduce costs associated with immunizations.

The current pandemic could lead to heightened demand for retail pharmacists and pharmacy technicians. 

"A major clinical and public health priority should be to decrease racial inequalities in mortality following the introduction of lifesavings drugs in the United States and worldwide.”

Investigators are evaluating a variety of medications for the novel coronavirus disease 2019 (COVID- 19), and the possible treatment landscape is rapidly evolving.

In the face of COVID-19, pharmacists continue to provide accessible care to patients.

Never before have so many brilliant minds, machines, and groups come together so quickly in an attempt to develop a vaccine.

Nearly 94% of survey respondents agreed that provider status is important for the future of pharmacy.

In July 2019, the FDA approved darolutamide (Nubeqa, Bayer) for men with prostate cancer that has not spread (ie, nonmetastatic) and no longer responds to medical or surgical treatment that lowers testosterone (ie androgen deprivation therapy).

Officials with the FDA granted Emergency Use Authorization (EUA) to the first diagnostic test that will allow at-home collection of saliva samples for coronavirus disease 2019 (COVID-19) testing.

The letter to congressional leaders warned that without reform, vulnerable populations could lose access to pharmacies, which are the first point-of-care for many.

Hydroxychloroquine has been widely used for treatment of COVID-19, despite the lack of strong evidence supporting its efficacy.

Here's a roundup of the latest coronavirus-related news.

In August 2019, the FDA approved entrectinib for treatment of adult patients with metastatic non-small cell lung cancer that is ROS1-positive.